Baxter contended in a Delaware Chancery Court lawsuit that an arbitration panel found Teva was bound by an agreement to cover liability stemming from cases that linked the development of hepatitis C in colonoscopy patients to tainted vials of propofol.
A Las Vegas jury ordered Teva and Baxter to pay more than $500 million in damages to a patient who contracted hepatitis C from a tainted propofol vial last year. This suit comes as a Las Vegas jury is hearing testimony in three more cases alleging officials from the two companies sold propofol in overly large vials that encourage medical personnel to reuse them.
In a February SEC filing, Teva officials said the indemnification agreement with Baxter “does not extend to punitive damages,” according to the report. The officials acknowledged in a later regulatory filing that an arbitration panel ruled 2-1 that the agreement covered punitive awards.
Related Articles on Anesthesia:
The Medicare Bundled Payment Initiative: An Alert From Anesthesia Business Consultants
American Society of Anesthesiologists Comments on 2012 CMS Physician Fee Schedule Proposed Rule
Physician Assistant’s License Suspended Over Fatal Anesthesia Error
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
